J Cancer 2021; 12(16):5005-5012. doi:10.7150/jca.58762 This issue Cite

Research Paper

Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer

Lijuan Yang1,2, Haohao Wu3, Yan Zhu2, Xiaoping Chen2, Youguo Chen1✉

1. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, P.R. China.
2. Department of Obstetrics and Gynecology, The First People's Hospital of Yancheng, Yancheng, Jiangsu, 224001, P.R. China.
3. Department of Radiotherapy, The First People's Hospital of Yancheng, Yancheng, Jiangsu, 224001, P.R. China.

Citation:
Yang L, Wu H, Zhu Y, Chen X, Chen Y. Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer. J Cancer 2021; 12(16):5005-5012. doi:10.7150/jca.58762. https://www.jcancer.org/v12p5005.htm
Other styles

File import instruction

Abstract

Graphic abstract

Objective: In this study, we aimed to evaluate the levels of plasma exosomal caveolin-1(CAV1) and determine its prognostic value in ovarian cancer patients.

Patients and Methods: Exosome-rich fractions were isolated from the plasma of 155 patients with ovarian cancer. TEM, NTA and western blot analysis were used to confirm the exosome integrity and purification.

Results: Compared with healthy controls, plasma exosomal CAV1 levels in ovarian cancer patient were significantly down-regulated (P < 0.001). The low plasma levels of exosomal CAV1 in ovarian cancer patient plasma were related to FIGO stages, grades and lymph node metastasis (all P < 0.01). Among all ovarian cancer patients, DFS was worse in patients who had low plasma exosomal CAV1 levels compared with that in patients with high plasma exosomal CAV1 levels (P < 0.001). The OS of patients with low plasma exosomal CAV1 levels was shorter than that in patients with high plasma exosomal CAV1 levels (P < 0.001). The AUROC of plasma exosomal CAV1 was 0.76 (95% CI: 0.68-0.82) for DFS prediction in ovarian cancer patients, with a sensitivity 52.9 (95% CI: 42.8-62.9) and a specificity 88.7 (95% CI: 77.0-95.7). For OS prediction in ovarian cancer patients, the AUROC of plasma exosomal CAV1 was 0.78 (95% CI: 0.70-0.84), with a sensitivity 65.1 (95% CI: 49.1-79.0) and a specificity 81.2 (95% CI: 72.8-88.0).

Conclusions: Low exosomal CAV1 levels were closely related to the FIGO stages I/II, low grade, lymph node metastasis and prognosis of ovarian cancer patients. Plasma exosomal CAV1 may be a potential biomarker for the prognosis in ovarian cancer patients.

Keywords: caveolin-1, ovarian cancer, exosomal, prognosis, biomarker


Citation styles

APA
Yang, L., Wu, H., Zhu, Y., Chen, X., Chen, Y. (2021). Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer. Journal of Cancer, 12(16), 5005-5012. https://doi.org/10.7150/jca.58762.

ACS
Yang, L.; Wu, H.; Zhu, Y.; Chen, X.; Chen, Y. Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer. J. Cancer 2021, 12 (16), 5005-5012. DOI: 10.7150/jca.58762.

NLM
Yang L, Wu H, Zhu Y, Chen X, Chen Y. Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer. J Cancer 2021; 12(16):5005-5012. doi:10.7150/jca.58762. https://www.jcancer.org/v12p5005.htm

CSE
Yang L, Wu H, Zhu Y, Chen X, Chen Y. 2021. Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer. J Cancer. 12(16):5005-5012.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image